UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 18, 2007
JOHNSON & JOHNSON
(Exact name of registrant as specified in its charter)
New Jersey 1-3215 22-1024240
(State or other Commission (I.R.S. Employer
jurisdiction File Number) Identification No.)
of incorporation)
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933
(Address of principal executive offices)
(zip code)
Registrant's telephone number including area code:
(732) 524-0400
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)
Item 2.02 Results of Operations and Financial Condition
On April 17, 2007, the Company issued supplemental tables of
sales of key products/franchises to its press release announcing
the Company's sales and earnings for the first quarter ended
April 1, 2007. These tables appear in Exhibit 99.1 to this
report and are incorporated herein by reference. In addition,
the press release reported operational sales growth rates on a
pro forma basis to include the net impact of the acquisition of
Pfizer Consumer Healthcare. A presentation of these pro forma
operational sales rates and the as reported operational sales
growth rates appears in Exhibit 99.2 to this report and is
incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
On April 17, 2007, during the first quarter 2007 earnings
conference call with the investment community, the Company raised
2007 full year adjusted earnings per share guidance to a range of
$4.02-$4.07*. This guidance reflects the Company's solid
financial performance in the first quarter of 2007, continued
cost control and the impact from its financing strategy. The
guidance includes the impact of the dilutive effect, excluding in-
process research & development, of the acquisition of Conor
Medsystems, Inc., which was completed in February 2007. The
Company also increased guidance for 2007 full year operational
sales growth to between 12.0% and 12.5%.
*Adjusted earning per share excludes in-process research and
development charges, as well as other special items.
(This report contains "forward-looking statements" as defined in
the Private Securities Litigation Reform Act of 1995. These
statements are based on current expectations of future events. If
underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could vary materially
from Johnson & Johnson's expectations and projections. Risks and
uncertainties include general industry conditions and
competition; economic conditions, such as interest rate and
currency exchange rate fluctuations; technological advances and
patents attained by competitors; challenges inherent in new
product development, including obtaining regulatory approvals;
domestic and foreign health care reforms and governmental laws
and regulations; and trends toward health care cost containment.
A further list and description of these risks, uncertainties and
other factors can be found in Exhibit 99 of the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2006.
Copies of this Form 10-K, as well as subsequent filings, are
available online at www.sec.gov or on request from Johnson &
Johnson. Johnson & Johnson does not undertake to update any
forward-looking statements as a result of new information or
future events or developments.)
Item 9.01 Financial Statements and Exhibits
Exhibit No. Description
99.1 Sales of Key Products/Franchises 1Q 2007
99.2 Presentation of Pro Forma Operational Sales Growth Rates
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
JOHNSON & JOHNSON
(Registrant)
Date: April 18, 2007 By: /s/ Stephen J. Cosgrove
Stephen J. Cosgrove
Controller
(Principal Accounting Officer)